Cohen Veterans Bioscience Open House at ISTSS

Cohen Veterans Bioscience attended the International Society for Traumatic Stress Studies (ISTSS) conference in New Orleans from November 4-7, 2015.

This meeting convened leading researchers in Post-Traumatic Stress Disorder (PTSD) and related conditions, such as suicidality and traumatic brain injury, and serves as a forum for investigators to present recent breakthroughs in the understand of PTSD and trauma-related disorders.

Cohen Veterans Bioscience held an Open House to meet investigatorsat the conference and to introduce its mission and its focus on translational research. This Open House was an opportunity for experts in trauma research to discuss:

  1. Factors that will drive the field of PTSD and trauma-related research forward
  2. Tools required for new innovations

At the Open House, Magali Haas, MD, PhD, CEO and President of Cohen Veterans Bioscience outlined the mission and goals of the organization to accelerate the discovery and development of new diagnostics, therapeutics and cures for PTSD and TBI. Dr. Haas also shared feedback from an online survey completed by investigators in advance of the Open House. There is significant enthusiasm for the establishment of a non-profit research organization that can help drive public-private partnerships for these conditions.

Learn more about the International Society for Traumatic Stress Studies (ISTSS) here.

Share this article:

More from CVB

https://www.cohenveteransbioscience.org/wp-content/uploads/2023/02/cvb-pr-2-21-23-data-visualization-featuredimage.jpg

Untapped potential of machine learning techniques for Parkinson’s Disease research and healthcare

https://www.cohenveteransbioscience.org/wp-content/uploads/2022/12/btb-action-summit-mh-cropped.jpg

Cohen Veterans Bioscience Announces ‘Call for National TBI Action Coalition’

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.